Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mixed Phenotype Acute Leukemia: early-phase trial registry
20 of 30 indexed Mixed Phenotype Acute Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 20 currently recruiting · #519 of 28,707 conditions by registered trial count
Mixed Phenotype Acute Leukemia: 30 US clinical trials tracked, 20 recruiting.
Mixed Phenotype Acute Leukemia is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition mixed-phenotype-acute-leukemia
OPEN 20 | RECR 67% | LATE 6 | EARLY 24 | RANK #519 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Mixed Phenotype Acute Leukemia lists 20 open slots (67% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mixed Phenotype Acute Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mixed Phenotype Acute Leukemia is recruiting above its size-band peers.
20 of 30 indexed trials (66.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mixed Phenotype Acute Leukemia research.
Fred Hutchinson Cancer Center accounts for 6 of 30 trials (20%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Mixed Phenotype Acute Leukemia enrolment sits around 78 participants.
Median target enrolment is 78 among the 30 trials that report a genuine target (sentinel values excluded). 17 of those (56.7%) plan for fewer than 100 participants.
-
Mixed Phenotype Acute Leukemia research is mostly interventional.
30 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
NCT03959085
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU
NCT04726241
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
NCT06289673
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
NCT04065399
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
NCT05602194
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT03802695
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology
NCT04067336
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06390319
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems
NCT07216443
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03779854
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
NCT04797767
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06013423
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT07356154
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx
NCT04872478
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
NCT05322850
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT06928662
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
NCT06034470
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Stanford University
NCT06551584
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
NCT04872790
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT03007147
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
NCT05457556
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04904588
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT05316701
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
NCT04128501
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT03843528
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
NCT02828358
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT02921061
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
NCT02135874
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 9 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mixed Phenotype Acute Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mixed Phenotype Acute Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mixed Phenotype Acute Leukemia page
30 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Mixed Phenotype Acute Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Mixed Phenotype Acute Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mixed Phenotype Acute Leukemia condition card totals 30 registered trials; most-linked intervention Cytarabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.